Severe Acute Respiratory Syndrome CoV 2 COVID-19 Survey and Vaccination Coverage in the Sickle Cell Population in Ile-De-France

Not Applicable

• Conditions: Sickle Cell Disease
• Interventions: Other: severe acute respiratory syndrome CoV-2 serology

• Registration Number: NCT05153044
• Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Brief Summary

The objective of this study is to determine the seroprevalence of severe acute respiratory syndrome-CoV-2 in unvaccinated sickle cell patients living in an area with high viral circulation and at risk of high viral transmission, after the 4th epidemic wave of COVID-19 in Ile-de -France, over a period of 3 months (for example, last quarter of 2021).

Detailed Description

Sickle cell disease is a very widespread genetic disease affecting 300,000 births worldwide, with a prevalence of one affected child for 1736 births in France, the most common genetic disease in France. France is the European country with the highest prevalence of the disease while Ile-de-France is the region with the highest prevalence of sickle cell disease and COVID-19. The medical management of sickle cell patients raises many challenges related to the complexity of their disease and the comorbidities that may be associated with their conditions (arterial hypertension, pulmonary arterial hypertension, nephropathy and renal failure, cerebral vasculopathy).Our seroprevalence study will focus on the sickle cell population living in an area with high circulation of severe acute respiratory syndrome-CoV-2; it will start after the 4th epidemic wave of COVID-19 during the vaccination campaigns, in order to collect on the one hand seroprevalence data (proportion of unvaccinated seropositive sickle cell patients) and persistence of humoral immunity (quantitative) after infection in unvaccinated subjects and on the other hand, to assess the vaccination coverage in this specific population (adults and adolescents) as well as its impact (occurrence of vaccine failures).

Study Timeline

• Status Verified: 2021-09
• Study First Submitted: 2021-10-28
• Study First Submitted QC: 2021-12-09
• Study First Posted: 2021-12-10
• Study Start: 2021-12-30
• Last Update Submitted: 2022-01-04
• Last Update Posted: 2022-01-05
• Primary Completion: 2022-09-10
• Study Completion: 2022-09-10

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 880

Inclusion Criteria

• Patient group = children with sickle cell disease:
• Children over 12 months of age and under 18 at the time of inclusion.
• Children with a major sickle cell syndrome (SS, "C gene and one sickle hemoglobin (S) gene", Sβ+, Sβ°, SE) followed in one of the centers of competence or reference for rare diseases (CRMR) "Major Sickle Cell Syndromes, Thalassemias and Other Rare Pathologies of Red Blood Cell and Erythropoiesis "from Ile de France.
• Children not subject to legal protection measures.
• Children affiliated to a French social security scheme
• Informed consent signed by one of the two parents.

Group of adults with sickle cell disease:

• Patients over 18 years of age at the time of inclusion (male, female).
• Patients with a major sickle cell syndrome (SS, "C gene and one sickle hemoglobin (S) gene", Sβ+, Sβ°, SE) followed in one of the centers of competence or reference for rare diseases (CRMR) "Major Sickle Cell Syndromes, Thalassemias and Other Rare Pathologies of Red Blood Cell and Erythropoiesis "from Ile de France.
• Patients not subject to legal protection measures.
• Patients affiliated to a French social security scheme
• Informed consent signed

Child-control group:

• Children over 12 months old and under 18 years old at the time of inclusion.
• Children without sickle cell disease
• Children monitored for asthma or with a history of asthma.
• Children not subject to legal protection measures.
• Children affiliated to a French social security scheme
• Informed consent signed by one of the two parents.

Exclusion Criteria

• Patient group = sickle cell children :
• Infants under 12 months of age.
• Other haemoglobinopathies and heterozygous Haemoglobin AS or AC patients.
• Children already in a treatment protocol or in the exclusion period from a previous investigation.
• Children on state medical assistance

Adult sickle cell group :

• Other haemoglobinopathies and heterozygous AS or AC patients.
• Patients already on a treatment protocol or in the exclusion period from a previous investigation.
• Pregnant or lactating women.
• Patients on state medical assistance

Child control group :

• Infants under 12 months of age and adults over 18 years of age.
• Children already in a treatment protocol or in the exclusion period from a previous study.
• Children on state medical assistance

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
sickle cell adult group	severe acute respiratory syndrome CoV-2 serology	sickle cell adult group
control children group	severe acute respiratory syndrome CoV-2 serology	control children group
sickle cell children group	severe acute respiratory syndrome CoV-2 serology	sickle cell children group

Primary Outcome Measures

Name	Time	Method
The positivity of total anti-SARS-CoV-2 blood Ig will be determined by the presence of anti-spike protein Ig G and / or anti-nucleocapsid Ig G (post-infectious COVID-19 humoral immunity).	9 months	To determine the seroprevalence of SARS-CoV-2 after the 4th epidemic wave in unvaccinated sickle cell patients (children and adults), living in an area with high viral circulation of SARS-CoV-2 and high risk of viral transmission, in Ile-De-France.

Secondary Outcome Measures

Name	Time	Method
The positivity anti-SARS-CoV-2 serology and anti-spike antibody titre from M0 to M6.	9 months	Compare the seroprevalence and decrease in antibodies (initial M0 titre and duration of persistence at M3-M6) in unvaccinated patients with a history of COVID-19 infection between the group of children with sickle cell disease, the group of children non-sickle cell control patients and the group of adults with sickle cell disease.
COVID-19 infection (nasopharyngeal RT-PCR Reverse transcription-polymerase chain reaction positivity and/or COVID-19 anti-SARS-CoV-2 serology).	9 months	Assessing factors associated with the risk of COVID-19 infection (epidemiological, environmental and sickle cell disease related) in sickle cell patients.
Proportion of patients vaccinated among the patients interviewed and included in the study.	9 months	Determine the vaccination coverage rate of the sickle cell population (according to age groups) over a period of 3 months, after the 4th epidemic wave of 2021.
Intensive care unit admission for COVID-19.	9 months	Assessing factors associated with a severe form of COVID-19 infection among sickle cell patients.
Negativity of anti-SARS-CoV-2 serology at M3 and M6.	3 and 6 months	Investigation of factors associated with a faster loss of anti-SARS-CoV-2 blood antibodies (age, sex, genotype, splenectomy, transplants, treatment with hydroxyurea) in unvaccinated sickle cell patients with a history of COVID-19 infection.
Occurrence of post-vaccine side effects (fever, pain, vaso-occlusive crisis, myocarditis, others)	9 months	List the occurrence of declared side effects.
Proportion of COVID-19 infection occurring in vaccinated patients.	9 months	Determine the incidence rate of COVID-19 infection in vaccinated patients (vaccine failure rate)